-
Research Infrastructure? No Offer Description Two fully-funded 3-year PhD studentships are available in Neuromorphic and Bio-inspired computing at the interface between control engineering, electrical
-
application of computational tools for the early detection and deconstruction of chromosomal instability in cancer” For further information about the research group, including their most recent publications
-
Two fully-funded 3-year PhD studentships are available in Neuromorphic and Bio-inspired computing at the interface between control engineering, electrical engineering, computational neuroscience
-
Science and Technology (CST) at the University of Cambridge. The goal of this PhD programme is to launch one "deceptive by design" project that combines the perspectives of human-computer interaction (HCI) and
-
The Centre for Doctoral Training in Nanoscience and Nanotechnology (NanoDTC) at the University of Cambridge invites applications for its 3.5-year interdisciplinary PhD programme. The programme
-
CAM-Doctoral Training Partnership is offering opportunities for ESRC-funded PhD studentships at Anglia Ruskin University, the University of Bedfordshire and the University of Cambridge starting in
-
considered. Qualifications/Skills PhD degree in a programme relevant to human-computer interaction and/or critical computing, ideally in Computer Science, Industrial Engineering, Interaction Design, or a
-
to the launch of the Bloomberg Cambridge University Corporate Bond Index later in 2025 and the delivery of the ongoing research programme related to the index project. The successful candidate will undertake desk
-
technologies, bulk and single-cell RNA-sequencing, flow cytometry, multiplex immunofluorescence, and standard molecular biology and biochemistry techniques. A computational component may also be available
-
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner) Course start date: 1st October 2026 Project details Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy Transfer (LET) alpha-particles to cancer cells, maximising efficacy while minimising toxicity. ...